Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Antithrombin III assay using a chromogenic substrate in newborns].

D De Mattia, O Montagna, E Marvulli

    Bollettino Della Societa Italiana Di Biologia Sperimentale
    |April 30, 1979
    PubMed
    Summary

    Antithrombin III (AT-III) activity in newborns is lower than adults, decreasing by the third day. Levels gradually increase, reaching half of adult concentrations by the seventh day of life.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Epidemiology of candidemia in neonatal intensive care units: a persistent public health problem.

    Annali di igiene : medicina preventiva e di comunita·2016
    Same author

    Magnetic resonance imaging screening of cerebral thromboembolic events in children with acute lymphoblastic leukemia: a pilot study.

    Neuropediatrics·2011
    Same author

    Invasive fungal infections in neonatal intensive care units of Southern Italy: a multicentre regional active surveillance (AURORA project).

    Journal of preventive medicine and hygiene·2011
    Same author

    Thyroid function and thyroid autoimmunity in childhood acute lymphoblastic leukemia off-therapy patients treated only with chemotherapy.

    Journal of endocrinological investigation·2009
    Same author

    Growth hormone deficiency and antipituitary antibodies in a patient with common variable immunodeficiency.

    Journal of endocrinological investigation·2009
    Same author

    Screening for children from families with Rendu-Osler-Weber disease: from geneticist to clinician.

    Journal of thrombosis and haemostasis : JTH·2006

    Area of Science:

    • Biochemistry
    • Neonatal Physiology
    • Hematology

    Context:

    • Antithrombin III (AT-III) is a crucial anticoagulant protein.
    • Understanding AT-III levels in newborns is vital for assessing thrombosis risk.
    • Limited data exists on early neonatal AT-III activity dynamics.

    Purpose:

    • To quantify antithrombin III activity in full-term newborns.
    • To characterize the developmental changes in AT-III levels during the first week of life.
    • To compare neonatal AT-III levels with those of adult individuals.

    Summary:

    • Chromogenic substrate assays were used to measure AT-III activity in 42 full-term newborns (1-7 days old).
    • AT-III levels were significantly lower in newborns compared to adults, particularly on days 1 and 3.
    • A gradual increase in AT-III levels was observed, reaching approximately 50% of adult concentrations by day 7.

    Impact:

    • Provides baseline data for neonatal AT-III activity.
    • Highlights the physiological immaturity of the neonatal coagulation system.
    • Informs clinical practice regarding thrombotic risk assessment in neonates.

    Related Experiment Videos